Bolt Biotherapeutics expects to raise about $120 million from a group of healthcare investors. It signed a Securities Purchase Agreement for 13,995.311 shares of Series D Non-Voting Convertible Preferred Stock at $8,574.30 each, for gross proceeds of $119,999,995. Investors include Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, and Deviation Capital. The deal also includes warrants to buy up to 6,997,655 common shares at an exercise price of $8.5743 per share on an as-converted basis. Each Series D share converts into 1,000 common shares, subject to conditions. The financing is expected to close on October 26, 2026.

SOLA Biosciences Japan has received a grant of approximately 6 billion yen over five years from the Japan Agency for Medical Research and Development. The funding will support development of SOL-257, a gene therapy designed to restore function of misfolded TDP-43 protein in amyotrophic lateral sclerosis patients. SOL-257 was developed using SOLA's JUMP70 platform, which targets disease-associated misfolded proteins whilst preserving normal ones. The therapy addresses TDP-43 mislocalisation, which occurs in approximately 97% of ALS cases. SOLA Biosciences Japan, a wholly owned subsidiary of Boston-based SOLA Biosciences, will serve as a central development hub in Japan. The programme is supported by Curie.Bio as lead investor, with UTEC participating. SOLA aims to advance SOL-257 towards human proof of concept in both the United States and Japan.